Please sign in to follow a disease.
Pulmovant, Inc.
Clinical trials sponsored by Pulmovant, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New combo therapy for lung scarring and high blood pressure under study Results expected Dec 2026 (estimated)
-
Inhaled drug aims to ease dangerous lung blood pressure in scarred lungs
Disease control Recruiting nowResearchers are testing an inhaled drug called mosliciguat in people who have pulmonary hypertension caused by interstitial lung disease, a condition where lung scarring leads to high blood pressure in the lungs. The phase 3 trial enrolls about 376 participants who receive either…
Phase 3 • Sponsor: Pulmovant, Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New combo therapy for lung scarring and high blood pressure under study
Disease control Recruiting nowThis study tests a new inhaled drug, mosliciguat, added to an existing treatment (treprostinil) for people with high blood pressure in the lungs caused by lung scarring. The goal is to see if the combination is safe and tolerable. About 20 adults with this condition will particip…
Phase 2 • Sponsor: Pulmovant, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC